BioPorto A/S (THOXF)
USD 0.29
(0.0%)
USD 0.29
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 81.35 Million DKK | -21.28% |
| 2022 | 97.98 Million DKK | 22.03% |
| 2021 | 80.29 Million DKK | 4.38% |
| 2020 | 76.92 Million DKK | -16.04% |
| 2019 | 91.62 Million DKK | 53.7% |
| 2018 | 59.61 Million DKK | 8.9% |
| 2017 | 54.74 Million DKK | 34.37% |
| 2016 | 40.74 Million DKK | 44.26% |
| 2015 | 28.24 Million DKK | -0.75% |
| 2014 | 28.45 Million DKK | -1.36% |
| 2013 | 28.84 Million DKK | 15.73% |
| 2012 | 24.92 Million DKK | 6.61% |
| 2011 | 23.37 Million DKK | 6.9% |
| 2010 | 21.86 Million DKK | -1.82% |
| 2009 | 22.27 Million DKK | 25.4% |
| 2008 | 17.76 Million DKK | 5.85% |
| 2007 | 16.78 Million DKK | 245.61% |
| 2006 | -11.52 Million DKK | 20.4% |
| 2005 | -14.47 Million DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 24.85 Million DKK | -68.07% |
| 2024 Q1 | 21.87 Million DKK | 16.85% |
| 2023 Q2 | 22.85 Million DKK | 2.67% |
| 2023 Q4 | 18.71 Million DKK | 13.33% |
| 2023 Q3 | 16.51 Million DKK | -27.73% |
| 2023 Q1 | 22.25 Million DKK | -12.57% |
| 2023 FY | 77.13 Million DKK | -21.28% |
| 2022 Q4 | 25.45 Million DKK | 5.3% |
| 2022 FY | 97.98 Million DKK | 22.03% |
| 2022 Q1 | 22.16 Million DKK | 3.03% |
| 2022 Q2 | 26.18 Million DKK | 18.16% |
| 2022 Q3 | 24.17 Million DKK | -7.69% |
| 2021 Q4 | 21.51 Million DKK | 17.14% |
| 2021 FY | 80.29 Million DKK | 4.38% |
| 2021 Q1 | 21.36 Million DKK | 29.52% |
| 2021 Q2 | 19.05 Million DKK | -10.84% |
| 2021 Q3 | 18.36 Million DKK | -3.6% |
| 2020 Q3 | 20.69 Million DKK | -1.27% |
| 2020 Q1 | 18.77 Million DKK | -9.52% |
| 2020 FY | 76.92 Million DKK | -16.04% |
| 2020 Q2 | 20.96 Million DKK | 11.68% |
| 2020 Q4 | 16.49 Million DKK | -20.29% |
| 2019 Q2 | 21.72 Million DKK | 6.24% |
| 2019 Q4 | 20.74 Million DKK | -27.75% |
| 2019 Q3 | 28.71 Million DKK | 32.2% |
| 2019 FY | 91.62 Million DKK | 53.7% |
| 2019 Q1 | 20.44 Million DKK | 45.21% |
| 2018 Q4 | 14.08 Million DKK | -5.03% |
| 2018 FY | 59.61 Million DKK | 8.9% |
| 2018 Q1 | 15.76 Million DKK | 220.32% |
| 2018 Q2 | 14.94 Million DKK | -5.16% |
| 2018 Q3 | 14.82 Million DKK | -0.82% |
| 2017 Q1 | -13.44 Million DKK | -36.94% |
| 2017 Q4 | -13.1 Million DKK | -9072.6% |
| 2017 Q3 | 146 Thousand DKK | 101.1% |
| 2017 FY | 54.74 Million DKK | 34.37% |
| 2017 Q2 | -13.29 Million DKK | 1.08% |
| 2016 Q4 | -9.81 Million DKK | 4.96% |
| 2016 FY | 40.74 Million DKK | 44.26% |
| 2016 Q1 | -9.33 Million DKK | -38.85% |
| 2016 Q2 | -11.26 Million DKK | -20.69% |
| 2016 Q3 | -10.32 Million DKK | 8.28% |
| 2015 Q1 | 7.12 Million DKK | 11.77% |
| 2015 Q3 | -5.82 Million DKK | -167.87% |
| 2015 Q4 | -6.72 Million DKK | -15.44% |
| 2015 Q2 | 8.57 Million DKK | 20.43% |
| 2015 FY | 28.24 Million DKK | -0.75% |
| 2014 Q1 | 6.81 Million DKK | 3.92% |
| 2014 FY | 28.45 Million DKK | -1.36% |
| 2014 Q3 | 6.5 Million DKK | 150.5% |
| 2014 Q4 | 6.37 Million DKK | -2.01% |
| 2014 Q2 | 2.59 Million DKK | -61.88% |
| 2013 Q1 | 6.4 Million DKK | 191.24% |
| 2013 FY | 28.84 Million DKK | 15.73% |
| 2013 Q3 | 8.85 Million DKK | 26.01% |
| 2013 Q4 | 6.55 Million DKK | -26.01% |
| 2013 Q2 | 7.02 Million DKK | 9.73% |
| 2012 Q4 | -7.02 Million DKK | -27.91% |
| 2012 Q2 | 5.52 Million DKK | -19.77% |
| 2012 Q1 | 6.88 Million DKK | 11.53% |
| 2012 Q3 | -5.48 Million DKK | -199.31% |
| 2012 FY | 24.92 Million DKK | 6.61% |
| 2011 Q1 | 5.63 Million DKK | -5.18% |
| 2011 Q3 | 3.91 Million DKK | -40.58% |
| 2011 Q4 | 6.17 Million DKK | 57.98% |
| 2011 FY | 23.37 Million DKK | 6.9% |
| 2011 Q2 | 6.58 Million DKK | 16.73% |
| 2010 Q2 | 5.04 Million DKK | -9.25% |
| 2010 Q4 | 5.94 Million DKK | 11.64% |
| 2010 Q3 | 5.32 Million DKK | 5.61% |
| 2010 FY | 21.86 Million DKK | -1.82% |
| 2010 Q1 | 5.55 Million DKK | 1.42% |
| 2009 Q3 | 5.35 Million DKK | -13.4% |
| 2009 Q1 | 5.25 Million DKK | 0.0% |
| 2009 FY | 22.27 Million DKK | 25.4% |
| 2009 Q4 | 5.47 Million DKK | 2.24% |
| 2009 Q2 | 6.18 Million DKK | 17.8% |
| 2008 FY | 17.76 Million DKK | 5.85% |
| 2007 FY | 16.78 Million DKK | 245.61% |
| 2006 FY | -11.52 Million DKK | 20.4% |
| 2005 FY | -14.47 Million DKK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -7655.386% |
| Arrayit Corporation | 6.19 Million USD | -1212.675% |
| Atlantic International Corp. | 5.57 Million USD | -1358.408% |
| Biocept, Inc. | 29.4 Million USD | -176.705% |
| Bioqual, Inc. | 7.44 Million USD | -992.18% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -10436.145% |
| DermTech, Inc. | 104.01 Million USD | 21.786% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 51.139% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | -259.597% |
| iMD Companies, Inc. | 151.8 Thousand USD | -53489.708% |
| IDenta Corp. | 662.97 Thousand USD | -12171.051% |
| Interpace Biosciences, Inc. | 20.23 Million USD | -302.106% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -209138.446% |
| InVitro International | 661.32 Thousand USD | -12201.686% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | -1046.154% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -139895.182% |
| Medical Imaging Corp. | 1.91 Million USD | -4154.551% |
| NovelStem International Corp. | 3.53 Million USD | -2199.565% |
| Optigenex Inc. | 1.28 Million USD | -6216.947% |
| PharmChem, Inc. | 2.93 Million USD | -2675.423% |
| Proteome Sciences plc | 3.26 Million USD | -2389.412% |
| Response Genetics, Inc | 25.31 Million USD | -221.316% |
| Rennova Health, Inc. | 7.67 Million USD | -959.602% |
| RushNet, Inc. | 1.78 Million USD | -4446.643% |
| ScreenPro Security Inc. | 3.23 Million USD | -2411.769% |
| Stella Diagnostics Inc. | 11.42 Million USD | -611.949% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | -1007.91% |
| Todos Medical Ltd. | 14.05 Million USD | -478.703% |